BR0015698A - Composições e métodos para tratamento de doenças alérgicas - Google Patents

Composições e métodos para tratamento de doenças alérgicas

Info

Publication number
BR0015698A
BR0015698A BR0015698-1A BR0015698A BR0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A BR 0015698 A BR0015698 A BR 0015698A
Authority
BR
Brazil
Prior art keywords
methods
compositions
allergic diseases
treating allergic
relates
Prior art date
Application number
BR0015698-1A
Other languages
English (en)
Inventor
Robert Llewellyn Clancy
Gerald Pang
Original Assignee
Probiall Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiall Pty Ltd filed Critical Probiall Pty Ltd
Publication of BR0015698A publication Critical patent/BR0015698A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE DOENçAS ALéRGICAS". A presente invenção refere-se a métodos de redução dos níveis de IgE e a métodos de tratamento de alergia, mediante administração de uma quantidade terapeuticamente eficaz de uma bactéria probiótica viva ou de uma composição contendo uma bactéria probiótica viva. A presente invenção também refere-se a métodos de identificação de uma bactéria probiótica útil e a composições contendo tal bactéria probiótica.
BR0015698-1A 1999-11-19 2000-11-20 Composições e métodos para tratamento de doenças alérgicas BR0015698A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases
PCT/AU2000/001414 WO2001037865A1 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders

Publications (1)

Publication Number Publication Date
BR0015698A true BR0015698A (pt) 2002-07-23

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015698-1A BR0015698A (pt) 1999-11-19 2000-11-20 Composições e métodos para tratamento de doenças alérgicas

Country Status (9)

Country Link
EP (1) EP1229930A4 (pt)
JP (1) JP2003514869A (pt)
KR (1) KR20020084066A (pt)
CN (1) CN1391480A (pt)
AU (1) AUPQ415899A0 (pt)
BR (1) BR0015698A (pt)
CA (1) CA2391499A1 (pt)
HK (1) HK1049115A1 (pt)
WO (1) WO2001037865A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
CN1767839B (zh) * 2003-03-13 2012-08-22 麒麟控股株式会社 抗过敏的组合物
JP4712289B2 (ja) * 2003-08-26 2011-06-29 株式会社エイ・エル・エイ 免疫促進用組成物
JP4591810B2 (ja) * 2003-09-19 2010-12-01 日之出産業株式会社 花粉症アレルギー性鼻炎抑制用点鼻組成物
AU2004298384A1 (en) * 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
TWI356680B (en) * 2007-01-05 2012-01-21 Promd Biotech Co Ltd Anti-allergy lactic acid bacteria
CN101328468B (zh) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 抗过敏的乳酸菌
CN102657260B (zh) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 抗过敏的乳酸菌
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
ES2950396T3 (es) 2008-02-01 2023-10-09 Prota Therapeutics Pty Ltd Un método para inducir tolerancia a un alérgeno
AU2011289592B2 (en) 2010-08-10 2014-06-12 R.P Scherer Technologies, Llc Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria
KR101311989B1 (ko) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품
EP3738599B1 (en) * 2018-01-12 2023-12-27 GI Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
CN111296842B (zh) * 2020-02-14 2021-01-05 赵一鸣 一种具有抗敏作用的益生菌组合物
CN112375722B (zh) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 一种改善过敏的干酪乳杆菌lc-12及其产品、应用
JP2025533686A (ja) 2022-10-14 2025-10-08 シーエスピー テクノロジーズ，インコーポレイティド 感湿性製品を貯蔵及び安定させるための容器及び方法
CN117085046A (zh) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 嗜酸乳杆菌ls001后生元及其应用
CN117887643B (zh) * 2024-03-14 2024-06-14 微康益生菌(苏州)股份有限公司 一种抗过敏的益生菌剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (ja) 1978-08-07 1984-11-13 極東脂肪酸株式会社 アレルギ−反応抑制剤
JPS5946491B2 (ja) 1979-03-14 1984-11-13 極東脂肪酸株式会社 喘息治療剤
JPH07265064A (ja) 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
JPH11199495A (ja) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk 腸溶性カプセルを用いた抗アレルギー剤
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
JP4074006B2 (ja) * 1998-06-24 2008-04-09 アサマ化成株式会社 ＩｇＥ抗体産生抑制物質の製造方法並びにそれを用いた食品

Also Published As

Publication number Publication date
AUPQ415899A0 (en) 1999-12-16
CN1391480A (zh) 2003-01-15
JP2003514869A (ja) 2003-04-22
HK1049115A1 (zh) 2003-05-02
WO2001037865A1 (en) 2001-05-31
CA2391499A1 (en) 2001-05-31
EP1229930A4 (en) 2004-09-22
KR20020084066A (ko) 2002-11-04
EP1229930A1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
ATE464371T1 (de) Antimikrobielle zusammensetzung
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
GB0223040D0 (en) Therapeutic compounds
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
PT705100E (pt) Guanidinas substituidas terapeuticas
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
DE602004013146D1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
DE69840027D1 (de) Synthetische peptidkonstrukte zur erkennung und behandlung von parodontose hervorgerufen durch porphyromonas gingivalis
BR0309435A (pt) Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
ATE267816T1 (de) Tan-1057 derivate
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
AU4568400A (en) Sphingomyelinase inhibitor
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PROBIALL PTY LIMITED (AU)

Free format text: ANOTADAS AS ALTERACOES DE SEDE CONFORME A PETICAO NO 020060046936/RJ DE 04/04/2006.

B25A Requested transfer of rights approved

Owner name: ROBERT CLANCY (AU)

Free format text: TRANSFERIDO DE: PROBIALL PTY LIMITED

B25A Requested transfer of rights approved

Owner name: DSM IP ASSETS B.V. (NL)

Free format text: TRANSFERIDO DE: ROBERT CLANCY

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.